Platelet Membrane Fragments Enhance the Procoagulant Effect of Recombinant Factor VIIa in Studies with Circulating Human Blood under Conditions of Experimental Thrombocytopenia

Seminars in Hematology

Volumn 41, Issue 1 SUPPL. 1, 2004, Pages 157-162

  Tonda, Raúl ^b   Galán, Ana M ^b   Mazzara, Roberto ^b   White, James G ^b   Ordinas, Antonio ^b   Escolar, Ginés ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING; BLOOD CLOTTING; CELL STRUCTURE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FIBRIN FORMATION; HEMOSTASIS; HUMAN; HUMAN CELL; IMMUNOLOCALIZATION; MORPHOMETRICS; NORMAL HUMAN; PRIORITY JOURNAL; SHEAR RATE; THROMBOCYTE MEMBRANE; THROMBOCYTOPENIA;

EID: 0842299569     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2003.11.026     Document Type: Conference Paper

References (27)

1. Alemany M, Hernandez MR, Bozzo J, et al: In vitro evaluation of the hemostatic effectiveness of non viable platelet preparations: Studies with frozen-thawed, sonicated or lyophilized platelets. Vox Sang 73:36-42, 1997
2. Bauer KA: Treatment of factor VII deficiency with recombinant factor VIIa. Haemostasis 26:155-158, 1996 (suppl)
3. Baumgartner HR: The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvasc Res 5:167-179, 1973
4. Blatt J, Gold SH, Wiley JM, et al: Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant 28:405-407, 2001
5. Chao FC, Kim BK, Houranieh AM, et al: Infusible platelet membrane microvesicles: A potential transfusion substitute for platelets. Transfusion 36:536-542, 1996
6. D'Oiron R, Menart C, Trzeciak MC, et al: Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thromb Haemost 83:644-647, 2000
7. Escolar G, Garrido M, Aznar-Salatti J: Comparison between human umbilical artery and rabbit abdominal aorta as substrata for platelet adhesion and platelet thrombus formation under flow conditions. Blood Vessels 28:520-531, 1991
8. Escolar G, Mazzara R, Castillo R, et al: The role of the Baumgartner technique in transfusion medicine: research and clinical applications. Transfusion 34:542-549, 1994
9. Galan AM, Bozzo J, Hernandez MR, et al: Infusible platelet membranes improve hemostasis in thrombocytopenic blood: Experimental studies under flow conditions. Transfusion 40: 1074-1080, 2000
10. Galan AM, Tonda R, Pino M, et al: Increased local procoagulant action: A mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in platelet disorders. Transfusion 43:885-892, 2003
11. Hedner U: Factor VIIa in the treatment of haemophilia. Blood Coagul Fibrinolysis 1:307-317, 1990
12. Hoffman M, Monroe DM: The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Dis Mon 49:14-21, 2003
13. Kjalke M, Monroe DM, Hoffman M, et al: Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation. Thromb Haemost 80:578-584, 1998
14. Kristensen J, Killander A, Hippe E, et al: Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 26:159-164, 1996 (suppl)
15. Lee DH, Blajchman MA: Novel treatment modalities: New platelet preparations and substitutes. Br J Haematol 114:496-505, 2001
16. Lisman T, Mosnier LO, Lambert T, et al: Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 99:175-179, 2002
17. Lozano M, Bos A, De Groot PG, et al: Suitability of low-molecular-weight heparin(oid)s and a pentasaccharide for an in vitro human thrombosis model. Arterioscler Thromb 14: 1215-1222, 1994
18. Monroe DM, Hoffman M, Oliver JA, et al: Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 99:542-547, 1997
19. Owens MR: The role of platelet microparticles in hemostasis. Transfus Med Rev 8:37-44, 1994
20. Poon MC, Demers C, Jobin F, et al: Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 94:3951-3953, 1999
21. Ruggeri ZM: Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 1:1335-1342, 2003
22. Schiffer CA: Management of patients refractory to platelet transfusion. Leukemia 15:683-685, 2001
23. Shapiro AD, Gilchrist GS, Hoots WK, et al: Prospective randomised trial of two doses of rFVIIa (NovoSeven®) in haemophilia patients with inhibitors undergoing surgery: Thromb Haemost 80:773-778, 1998
24. Sultan Y, Loyer F: In vitro evaluation of factor-VIII bypassing activity of activated prothrombin complex concentrate, prothrombin complex concentrate, and factor-VIIa in the plasma of patients with factor-VIII inhibitors-Thrombin generation test in the presence of collagen-activated platelets. J Lab Clin Med 121:444-452, 1993
25. Teitel JM: The factor-VIII bypassing activity of prothrombin complex concentrates-The roles of factor VIIa and endothelial cell tissue factor. Thromb Haemost 66:559-564, 1991
26. Tengborn L, Petruson B: A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 75:981-982, 1996
27. Weiss HJ, Baumgartner HR, Turitto VT: Regulation of platelet-fibrin thrombi on subendothelium. Ann NY Acad Sci 516:380-397, 1987